100 related articles for article (PubMed ID: 8184567)
41. Prognostic significance of plasma cell propidium iodide and annexin-V indices and their mutual ratio in multiple myeloma.
Scudla V; Ordeltova M; Minarik J; Dusek L; Zemanova M; Bacovsky J
Neoplasma; 2006; 53(3):213-8. PubMed ID: 16652190
[TBL] [Abstract][Full Text] [Related]
42. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
Bhatti SS; Kumar L; Dinda AK; Dawar R
Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
[TBL] [Abstract][Full Text] [Related]
43. Serum thymidine kinase in monoclonal gammopathies. A prospective study. The Cooperative Group for Study and Treatment of Multiple Myeloma.
Luoni R; Ucci G; Riccardi A; Gobbi P; Avato FM; Vignale C; Ascari E
Cancer; 1992 Mar; 69(6):1368-72. PubMed ID: 1540874
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of serum deoxythymidine kinase as a marker in multiple myeloma.
Simonsson B; Källander CF; Brenning G; Killander A; Ahre A; Gronowitz JS
Br J Haematol; 1985 Oct; 61(2):215-24. PubMed ID: 4041368
[TBL] [Abstract][Full Text] [Related]
45. International staging system for multiple myeloma.
Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
[TBL] [Abstract][Full Text] [Related]
46. Prognostic factors and staging systems of multiple myeloma:
Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
[TBL] [Abstract][Full Text] [Related]
47. Chronobiological circadian aspects of serum lactate dehydrogenase and serum thymidine kinase in monitoring multiple myeloma.
Pasqualetti P; Casale R; Collacciani A
Am J Hematol; 1996 Feb; 51(2):176-7. PubMed ID: 8579069
[No Abstract] [Full Text] [Related]
48. [Low-dose thalidomide in refractory and relapsing multiple myeloma].
Radocha J; Maisnar V
Vnitr Lek; 2007 Feb; 53(2):129-34. PubMed ID: 17419173
[TBL] [Abstract][Full Text] [Related]
49. Prognostic factors in multiple myeloma: selection using Cox's proportional hazard model.
Pasqualetti P; Collacciani A; Maccarone C; Casale R
Biomed Pharmacother; 1996; 50(1):29-35. PubMed ID: 8672729
[TBL] [Abstract][Full Text] [Related]
50. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
51. Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy.
Foekens JA; Romain S; Look MP; Martin PM; Klijn JG
Cancer Res; 2001 Feb; 61(4):1421-5. PubMed ID: 11245445
[TBL] [Abstract][Full Text] [Related]
52. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma.
Kaiser M; Mieth M; Liebisch P; Oberländer R; Rademacher J; Jakob C; Kleeberg L; Fleissner C; Braendle E; Peters M; Stover D; Sezer O; Heider U
Eur J Haematol; 2008 Jun; 80(6):490-4. PubMed ID: 18331598
[TBL] [Abstract][Full Text] [Related]
53. Significance of thymidine kinase activity in renal cell carcinoma.
Mizutani Y; Wada H; Yoshida O; Fukushima M; Nakao M; Miki T
J Urol; 2003 Feb; 169(2):706-9. PubMed ID: 12544347
[TBL] [Abstract][Full Text] [Related]
54. Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients.
Corso A; Arcaini L; Mangiacavalli S; Astori C; Orlandi E; Lorenzi A; Passamonti F; Klersy C; Pascutto C; Canevari-Sciorati A; Lazzarino M
Haematologica; 2001 Apr; 86(4):394-8. PubMed ID: 11325645
[TBL] [Abstract][Full Text] [Related]
55. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon?
Baur A; Stäbler A; Nagel D; Lamerz R; Bartl R; Hiller E; Wendtner C; Bachner F; Reiser M
Cancer; 2002 Sep; 95(6):1334-45. PubMed ID: 12216103
[TBL] [Abstract][Full Text] [Related]
56. Anion gap among patients of multiple myeloma and normal individuals.
Mansoor S; Siddiqui I; Adil S; Nabi Kakepoto G; Fatmi Z; Ghani F
Clin Biochem; 2007 Feb; 40(3-4):226-9. PubMed ID: 17156769
[TBL] [Abstract][Full Text] [Related]
57. Biochemical markers in multiple myeloma: a multivariate analysis.
Simonsson B; Källander CF; Brenning G; Killander A; Gronowitz JS; Bergström R
Br J Haematol; 1988 May; 69(1):47-53. PubMed ID: 3289607
[TBL] [Abstract][Full Text] [Related]
58. [Basic examination of deoxythymidine kinase using Prolifigen TK kit "Daiichi"].
Sadamori N; Yamaguchi K; Hakariya S; Mine M; Hayashibara T; Kawachi T; Sasagawa I; Iwasaki H; Kinoshita H; Hayashi K
Rinsho Ketsueki; 1990 Nov; 31(11):1806-11. PubMed ID: 2287065
[TBL] [Abstract][Full Text] [Related]
59. Serum deoxythymidine kinase: no help in the diagnosis and prognosis of monoclonal gammopathy.
Bäck H; Jagenburg R; Rödjer S; Westin J
Br J Haematol; 1993 Aug; 84(4):746-8. PubMed ID: 8217837
[TBL] [Abstract][Full Text] [Related]
60. [Determination of thymidine kinase in the cerebrospinal fluid as a marker of leukemic meningosis].
Musto P; Cascavilla N; Ladogana S; Modoni S; Carotenuto M
Medicina (Firenze); 1989; 9(1):49-51. PubMed ID: 2739531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
